Eliem Therapeutics

Redmond, WA, US

Eliem Therapeutics develops drug candidates for nervous system disorders, including chronic pain, mood disorders and epilepsy. It aims to provide new treatment options for people affected by these conditions.

Facts

HQ
Redmond, WA, US
Sectors
Biotech, Pharmaceuticals, Healthcare
Stage
Public
Members see funding amounts.
.

Is this your organization? Claim it

Recent coverage

Front-page news, podcasts and videos about Eliem Therapeutics

See all 6

Eliem Therapeutics raises $80M in IPO, prices 6.4M shares at $12.50 and lists on Nasdaq as ELYM

Eliem Therapeutics priced 6.4 million shares at $12.50 in an IPO that raised $80 million and will trade on Nasdaq as ELYM, with shares closing at $15.90 (up 27%). The Redmond biotech, founded ~3 years ago and led by Bob Azelby, is early-stage with no product revenue, a $46.7M deficit, 25 employees, and is developing CNS-focused therapies for pain, psychiatry and epilepsy.

Eliem Therapeutics files for Nasdaq IPO to raise up to $80M after $140M private funding; to trade as ELYM

Eliem Therapeutics, a Redmond clinical-stage biotech developing treatments for pain and mood disorders, filed for a Nasdaq IPO under ticker ELYM seeking up to $80 million after raising $140 million in private funding this year. The company, founded in 2019 and led by CEO Bob Azelby, is advancing ETX-810 (phase 2a for neuropathic pain) and ETX-155 (for mood disorders and epilepsy).

Questions about Eliem Therapeutics

What is Eliem Therapeutics?

Redmond, WA, US

Who invested in Eliem Therapeutics, and how much has it raised?

Members of Seattle Flow see Eliem Therapeutics' funding rounds, amounts and investors on its Funding tab. Joining is free.

Where is Eliem Therapeutics based?

Eliem Therapeutics is headquartered in Redmond, WA, US.